Kyle Lahucik

AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after their $18.5B obesity alliance and two deals in previous years.

Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of Phase 3 data.

Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.

Biotech Correspondent A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy …

Novartis, Vertex, Ipsen and United Therapeutics kick off second-half M&A activity with up to $12.6B in new deals, extending a 45-deal run from 2026's first half.

Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs & sleep disorders.

Copy Chief and News Editor Biotech Correspondent Senior Biopharma Correspondent

Apnimed files for Nasdaq IPO under the ticker $APMD, three months after submitting its sleep apnea drug AD109 for FDA approval.

Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.

After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet.